Earnings Update Could Be A Game Changer For Harmony Biosciences Stock (HRMY)

• Harmony Biosciences Holdings reported third quarter 2026 net income of US$48.2 million with diluted EPS from continuing operations of US$0.81, alongside nine month net income of US$156.12 million and diluted EPS of US$2.63.
• The mixed pattern, with a softer third quarter but higher nine month earnings versus the prior year, highlights how the timing of costs and demand can shift reported profitability within a year for Harmony Biosciences Holdings.
• Investors may now consider how Harmony Biosciences Holdings' softer third quarter EPS, together with stronger year to date profits, could influence its overall investment narrative.

Scan beyond Harmony Biosciences Holdings and compare this earnings pattern with hand-picked companies showing resilient profitability in our 29 resilient stocks with low risk scores

Harmony Biosciences Holdings Investment Narrative Recap

For Harmony Biosciences Holdings, the core belief is that WAKIX can keep funding a broader rare neurology pipeline while intellectual property protection holds and new indications mature. The latest results show a modest dip in third quarter profit compared to last year, while the nine month figures are higher. That mix points to timing effects rather than a clear break in the operating story.

The key short term catalyst remains progress in late stage pitolisant programs and orexin 2 agonist BP1.15205, which aim to reduce reliance on a single product. The biggest current risk is still concentration in WAKIX and rising cost of goods, which nine month profitability does not fully resolve. This quarter’s pattern does not appear to be a material shift in that risk balance.

The most relevant announcement here is the third quarter 2026 earnings release itself. Net income for the quarter of US$48.2 million compares with US$50.87 million a year earlier, while nine month profit of US$156.12 million compares with US$136.2 million. Basic and diluted EPS from continuing operations follow the same pattern of slightly softer quarterly figures and stronger year to date numbers.

For catalysts, that combination suggests Harmony Biosciences Holdings is still generating enough profit to support its clinical and formulation work around pitolisant GR, high dose pitolisant and programs like Prader Willi syndrome and idiopathic hypersomnia. The main question for you is whether this earnings profile gives the business enough financial headroom to keep pushing those projects forward while managing WAKIX concentration and future generic risk.

Harmony Biosciences Holdings' narrative projects US$1.4b revenue and US$363.2 million earnings by 2029. This implies 12.5% yearly revenue growth and roughly a 2x earnings increase from US$181.3 million.

Uncover why Harmony Biosciences Holdings' fair value indicates a 44% potential upside to its current price that could narrow quickly.

Exploring Other Perspectives

One alternate view focuses less on WAKIX exclusivity and more on earnings power. The most bearish analysts were pencilling in revenue of about US$1.0b and earnings of US$233.1 million by 2029, far below the consensus of US$1.4b and US$363.2 million. This third quarter update could eventually push those expectations in either direction.

Explore 3 other Harmony Biosciences Holdings fair value estimates, including one that suggests it could be worth just $47.64!

Decide For Yourself

Don't just follow the ticker, dig into the data and build a conviction that's truly your own.

• A great starting point for your Harmony Biosciences Holdings research is our analysis highlighting 3 key rewards that could impact your investment decision.
• See our latest analysis for Harmony Biosciences Holdings. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Harmony Biosciences Holdings' overall financial health at a glance.

Looking For More Investment Ideas Beyond Harmony Biosciences Holdings?

Once you have a view on Harmony Biosciences Holdings, it can help to line that up against other opportunities that share the qualities you care about most.

• If capital preservation and steadier returns matter to you, compare Harmony Biosciences Holdings with 29 resilient stocks with low risk scores that have historically shown lower risk scores and more resilient profiles.
• If potential mispricing is your focus, scan a 39 high quality undervalued stocks that combine solid fundamentals with prices below their assessed worth.
• If income is a priority, weigh Harmony Biosciences Holdings against 8 dividend fortresses that pair 5%+ yields with an emphasis on stability.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com